PF-3845 RB597 b-AP15 (NSC686852)

b-AP15 (NSC686852)

Oral Aticaprant (CERC-501) administration selectively and potently occupies central kappa opioid receptors (ED50=0

5 nM) with antagonistic activity on androgen receptor (EC50=420

30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11

ML-792 is a mechanism-based SUMO-activating enzyme (SAE) inhibitor with nanomolar potency in cellular assays

PF-3845 RB597 b-AP15 (NSC686852)PF 3845 is a fatty acid amide hydrolase (FAAH) inhibitor, and acts in the nervous system to reverse LPS induced tactile allodynia in mice. PF 3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Treatment with PF3845 inactivated FAAH activity and enhanced the AEA levels in the brain. It reduced neurodegeneration in the dentate gyrus, and up regulated the expression of Bcl 2 and